tirzepatide vs compounded semaglutide vs. Tirzepatide: What It Does, How

Compounded semaglutide with glycine is cheaper, but this combination is prepared in compounding pharmacies

What the dual GLP-1/GIP data means for buyers right now

Quick Takeaways Retatrutide (GLP-1/GIP/glucagon receptor agonist) shows up to 2428.7% body weight loss in Phase 2 & 3 trials, outperforming both Tirzepatide and Semaglutide but not yet FDA-approved Tirzepatide (GLP-1/GIP receptor agonist) delivers 2022.5% weight loss and is FDA-approved, beating Semaglutide by ~47% in head-to-head trials Semaglutide (GLP-1 receptor agonist) produces 1415% weight loss and remains the most widely prescribed, but is mechanistically inferior to dual and triple agonists All three share gastrointestinal side effects

The combined use of Tesamorelin and Ipamorelin has also shown significant benefits for muscle growth and fat loss, particularly among fitness enthusiasts